Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2015, Pages

  Kwon Chung, Kyung J ^a   Fraser, James A ^b   Doering, T Ámara L ^c   Wang, Zhuo A ^c   Janbon, Guilhem ^d   Idnurm, Alexander ^e   Bahn, Yong Sun ^f  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; MELANIN; VIRULENCE FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL RESISTANCE; ARTICLE; BODY TEMPERATURE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DNA SEQUENCE; ECOLOGY; ENVIRONMENTAL EXPOSURE; ENZYME DEGRADATION; FUNGAL CAPSULE; FUNGAL VIRULENCE; FUNGUS GROWTH; GENETIC DIFFERENCE; GENETIC REGULATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOGENESIS; INFECTION RISK; LIFE CYCLE STAGE; LIFE HISTORY; MAMMAL; MELANOGENESIS; MENINGOENCEPHALITIS; MOLECULAR EPIDEMIOLOGY; MYCOLOGY; NOMENCLATURE; NONHUMAN; PHENOTYPIC VARIATION; RISK ASSESSMENT; RISK FACTOR; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SPECIES DIVERSITY; STRESS; TAXONOMY;

BASIDIOMYCOTA; CANDIDA; CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 84923800100     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a019760     Document Type: Article

References (252)

1. Ajello L. 1958. Occurrence of Cryptococcus neoformans in soil. Am JHyg 67: 72-77.
2. Akhter S, McDade HC, Gorlach JM, Heinrich G, Cox GM, Perfect JR. 2003. Role of alternative oxidase gene in path-ogenesis of Cryptococcus neoformans. Infect Immun 71: 5794-5802.
3. Alspaugh JA, Pukkila-Worley R, Harashima T, Cavallo LM, Funnell D, Cox GM, Perfect JR, Kronstad JW, Heitman J. 2002. Adenylyl cyclase functions downstream of the Ga protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell 1: 75-84.
4. Bahn YS, Jung KW. 2013. Stress signaling pathways for the pathogenicity of Cryptococcus. Eukaryot Cell 12: 1564-1577.
5. Bahn Y-S, Cox GM, Perfect JR, Heitman J. 2005a. Carbonic anhydrase and CO2 sensing during Cryptococcus neofor-mans growth, differentiation, and virulence. CurrBiol 15: 2013-2020.
6. Bahn YS, Kojima K, Cox GM, Heitman J. 2005b. Special-ization of the HOG pathway and its impact on differen tiation and virulence of Cryptococcus neoformans. Mol Biol Cell 16: 2285-2300.
7. Baker RD. 1976. The primary pulmonary lymph node com-plexofcrytptococcosis. Am JClin Pathol 65: 83-92.
8. Bar-Peled M, Griffith CL, Doering TL. 2001. Functional cloning and characterization of a UDP-glucuronic acid decarboxylase: The pathogenic fungus Cryptococcus neo-formans elucidates UDP-xylose synthesis. Proc Natl Acad Sci 98: 12003-12008.
9. Bar-Peled M, Griffith CL, Ory JJ, Doering TL. 2004. Biosyn-thesis of UDP-GlcA, a key metabolite for capsular poly-saccharide synthesis in the pathogenic fungus Cryptococ cus neoformans. Biochem J 381: 131-136.
10. Bauwens L, Charles A, Bekker LG. 1986. Isolation of Cryp-tococcus neoformans var. neoformans in the aviaries ofthe Antwerp zoological gardens. Mykosen 29: 291-294.
11. Benham RW. 1935. Cryptococci, their identification by morphology and serology. J Infect Dis 57: 255-274.
12. Benham RW. 1950. Cryptococcosis and blastomycosis. Ann NYAcadSci 50: 1299-1314.
13. Bennett JE, Kwon-Chung KJ, Theodore TS. 1978. Biochem-ical differences between serotypes ofCryptococcus neofor-mans. Sabouraudia 16: 168-175.
14. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, et al. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301: 126-131.
15. Beverley SM, Owens KL, Showalter M, Griffith CL, Doering TL, Jones VC, McNeil MR. 2005. Eukaryotic UDP-ga-lactopyranose mutase (GLF gene) in microbial and meta-zoal pathogens. Eukaryot Cell 4: 1147-1154.
16. Billmyre RB, Calo S, Feretzaki M, Wang X, Heitman J. 2013. RNAi function, diversity, and loss in the fungal king dom. Chromosome Res 21: 561-572.
17. Blasi E, Barluzzi R, Mazzolla R, Tancini B, Saleppico S, Puliti M, Pitzurra L, Bistoni F. 1995. Role of nitric oxide and melanogenesis in the accomplishment of anticryptococ-cal activity by the BV-2 microglial cell line. J Neuroim-munol 58: 111-116.
18. Brown SM, Campbell LT, Lodge JK. 2007. Cryptococcus neo-formans, a fungus under stress. Curr Opin Microbiol 10: 320-325.
19. Busse O. 1894. Uber parasitare Zelleinschlusse und ihre Zuchtung [About parasitic cell enclosures and their gen-eration]. ZBacteriol 16: 175-180.
20. Busse O. 1895. Uber Saccharomycosis hominis [About Sac-charomycosis hominis]. Virchows Arch A 140: 23-46.
21. Byrnes EJ, Heitman J. 2009. Cryptococcus gattii outbreak expands into the Northwestern United States with fatal consequences. F1000 Biol Rep 6262.
22. Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, May RC, et al. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6: e1000850.
23. Byrnes EJ 3rd, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: An emerging fungal pathogen infect-ing humans and animals. Microbes Infect 13: 895-907.
24. Cadieux B, Lian T, Hu G, Wang J, Biondo C, Teti G, Liu V, Murphy ME, Creagh AL, Kronstad JW. 2013. The Man-noprotein Cig1 supports iron acquisition from heme and virulence in the pathogenic fungus Cryptococcus neofor-mans. J Infect Dis 207: 1339-1347.
25. Casadevall A, Perfect JR. 1998. Cryptococcus neoformans. ASM, Washington, DC.
26. Casadevall A, Pirofski LA. 2007. Accidental virulence, cryp-tic pathogenesis, Martians, lost hosts, and the pathoge-nicityof environmental microbes. Eukaryot Cell 6:2169-2174.
27. Castellani A. 1931. An amoeba growing in culture of ayeast. J Trop Med Hyg 33: 188-191.
28. Castle SA, Owuor EA, Thompson SH, Garnsey MR, Klutts JS, Doering TL, Levery SB. 2008. fS1,2-Xylosyltransferase Cxt1p is solely responsible for xylose incorporation into Cryptococcus neoformans glycosphingolipids. Eukaryot Cell 7: 1611-1615.
29. Chang YC, Kwon-Chung KJ. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14: 4912-4919.
30. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, Paul-Satyaseela M, Kim KS, Kwon-Chung KJ. 2004. Cryptococcal yeast cells invade the central nervous K.J. Kwon-Chung et al. system via transcellular penetration of the blood-brain barrier. Infect Immun 72: 4985-4995.
31. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung KJ. 2007. Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans. Mol Microbiol 64: 614-629.
32. Chaskes S, Tyndall RL. 1975. Pigment production by Cryp-tococcus neoformansfrompara-and ortho-diphenols: Ef-fect ofthe nitrogen source. JClin Microbiol 1: 500-514.
33. Chayakulkeeree M, Johnston SA, Oei JB, Lev S, Williamson PR, Wilson CF, Zuo X, Leal AL, Vainstein MH, Meyer W, et al. 2011. SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Mol Microbiol 80: 1088-1101.
34. Chen SC, Muller M, Zhou JZ, Wright LC, Sorrell TC. 1997. Phospholipase activity in Cryptococcus neoformans: A new virulence factor? J Infect Dis 175: 414-420.
35. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K. 2000. Epidemiol-ogy and host and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499-508.
36. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. 2008. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14: 755-762.
37. Chen Y-L, Lehman VN, Lewit Y, Averette AF, Heitman J. 2013. Calcineurin governs thermotolerance and viru-lence of Cryptococcus gattii. G3 (Bethesda) 3: 527-539.
38. Cherniak R, Valafar H, Morris LC, Valafar F. 1998. Crypto-coccus neoformans chemotyping by quantitative analysis of1H nuclear magnetic resonance spectra ofglucuronox-ylomannans with a computer-simulated artificial neural network. Clin Diagn Lab Immunol 5: 146-159.
39. Choi J, Vogl AW, Kronstad JW. 2012. Regulated expression of cyclic AMP-dependent protein kinase A reveals an influ-ence on cell size and the secretion of virulence factors in Cryptococcus neoformans. MolMicrobiol 85: 700-715.
40. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. 2002. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 186: 522-530.
41. Chun CD, Liu OW, Madhani HD. 2007. A link between virulence and homeostatic responses to hypoxia during infection by the human fungal pathogen Cryptococcus neoformans. PLoS Pathog 3: e22.
42. Chung S, Mondon P, Chang YC, Kwon-Chung KJ. 2003. Cryptococcus neoformans with a mutation in the tetratri-copeptide repeat-containing gene, CCN1, causes subcu-taneous lesions but fails to cause systemic infection. Infect Immun 71: 1988-1994.
43. Cottrell TR, Griffith CL, Liu H, Nenninger AA, Doering TL. 2007. The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule syn-thesis. Eukaryot Cell 6: 776-785.
44. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. 2000. Urease as a virulence factor in experimental cryp-tococcosis. Infect Immun 68: 443-448.
45. Cox GM, McDade HC, Chen SC, Tucker SC, Gottfredsson M, Wright LC, Sorrell TC, Leidich SD, Casadevall A, Ghannoum MA, et al. 2001. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. MolMicrobiol 39: 166-175.
46. Cox GM, Harrison TS, McDade HC, Taborda CP, Heinrich G, Casadevall A, Perfect JR. 2003. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun 71: 173-180.
47. Cramer KL, Gerrald QD, Nichols CB, Price MS, Alspaugh JA. 2006. Transcription factor Nrg1 mediates capsule for-mation, stress response, and pathogenesis in Cryptococcus neoformans. Eukaryotic Cell 5: 1147-1156.
48. Curtis F. 1986. Contribution a l'etude de la saccharomycose humaine [Contribution to the studyofhuman saccharo-mycosis]. Ann Inst Pasteur 10: 449-468.
49. de Hoog GS, Hasse G, Chaturvedi V, Walsh TJ, Meyer W, Lackner M. 2013. Taxonomyofmedically important fungi in the molecular era. Lancet Infect Dis 13: 385-386.
50. Ding C, Yin J, Tovar EM, Fitzpatrick DA, Higgins DG, Thiele DJ. 2011. The copper regulon of the human fungal path-ogen Cryptococcus neoformans H99. Mol Microbiol 81: 1560-1576.
51. Ding C, Festa RA, Chen YL, Espart A, Palacios O, Espin J, Capdevila M, Atrian S, Heitman J, Thiele DJ. 2013. Cryptococcus neoformans copper detoxification machinery is critical for fungal virulence. Cell Host Microbe 13: 265-276.
52. Doering TL. 2009. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neofor-mans. Annu Rev Microbiol 63: 223-247.
53. Doering TL, Nosanchuk JD, Roberts WK, Casadevall A. 1999. Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol 37: 175-181.
54. Dromer F, Casadevall A, Perfect JR, Sorrell T. 2011. Crypto-coccus neoformans: Latency and disease. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 431-439. ASM, Washington, DC.
55. D'Souza CA, Kronstad JW, Taylor G, Warren R, Yuen M, Hu G, Jung WH, Sham A, Kidd SE, Tangen K, et al. 2011. Genome variation in Cryptococcus gattii, an emerg-ing pathogen of immunocompetent hosts. mBio 2: e00342-10.
56. Dykstra MA, Friedman L, Murphy JW. 1977. Capsule size of Cryptococcus neoformans: Control and relationship to virulence. InfectImmun 16: 129-135.
57. Edman JC, Kwon-Chung KJ. 1990. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol Cell Biol 10: 4538-4544.
58. Eisenman HC, Frases S, Nicola AM, Rodrigues ML, Casadevall A. 2009. Vesicle-associated melanization in Cryptococcus neoformans. Microbiol 155: 3860-3867.
59. Ellis DH, Pfeiffer TJ. 1990. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 28: 1642-1644.
60. Emmons CW. 1951. Isolation of Cryptococcus neoformans from soil. J Bacteriol 62: 685-690.
61. Emmons CW. 1955. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am JHyg 62: 227-232. C. neoformans and C. gattii in Cryptococcosis.
62. Evans EE. 1950. The antigenic composition ofCryptococcus neoformans: 1. A serologic classification by means of the capsular and agglutination reactions. J Immunol 64: 423-430.
63. Feretzaki M, Heitman J. 2013. Genetic circuits that govern bisexual and unisexual reproduction in Cryptococcus neo-formans. PLoS Genet 9: e1003688.
64. Ferreira GF, Baltazar Lde M, Santos JR, Monteiro AS, Fraga LA, Resende-Stoianoff MA, Santos DA. 2013. The role of oxidative and nitrosative bursts caused by azoles and am-photericin B against the fungal pathogen Cryptococcus gattii. J Antimicrobial Chemother 68: 1801-1811.
65. Fonseca FL, Nimrichter L, Cordero RJ, Frases S, Rodrigues J, Goldman DL, Andruszkiewicz R, Milewski S, Travassos LR, Casadevall A, et al. 2009. Role for chitin and chito-oligomers in the capsular architecture of Cryptococcus neoformans. Eukaryot Cell 8: 1543-1553.
66. Fonseca A, Boekhout T, Fell JW. 2011. Cryptococcus Vuille-min (1901). In The yeasts: A taxonomic study, Vol. 3 (ed. Kurtzman CP, Fell JW, Boekhout T), pp. 1661-1745. Elsevier, Amsterdam.
67. Fox DS, Cruz MC, Sia RA, Ke H, Cox GM, Cardenas ME, Heitman J. 2001. Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol Micro-biol 39: 835-849.
68. Franzot SP, Salkin IF, Casadevall A. 1999. Cryptococcus neo-formans var grubii: Separate varietal status for Cryptococ-cus neoformans serotype A. JClin Microbiol 37: 838-840.
69. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, Stajich JE, Dietrich FS, Perfect JR, et al. 2005a. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437: 1360-1364.
70. Fraser JA, Huang JC, Pukkila-Worley R, Alspaugh JA, Mitchell TG, Heitman J. 2005b. Chromosomal translo-cation and segmental duplication in Cryptococcus neofor-mans. Eukaryot Cell 4: 401-406.
71. Frases S, Nimrichter L, Viana NB, Nakouzi A, Casadevall A. 2008. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell 7: 319-327.
72. Fries BC, Chen F, Currie BP, Casadevall A. 1996. Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol 34: 1531-1534.
73. Fu J, Morris IR, Wickes BL. 2013. The production ofmono-karyotic hyphae by Cryptococcus neoformans can be in-duced by high temperature arrest of the cell cycle and is independent of same-sex mating. PLoS Pathog 9: e1003335.
74. Galanis E, Macdougall L, Kidd S, Morshed M. 2010. Epide-miologyofCryptococcusgattii,BritishColumbia,Canada,1999-2007. EmergInfectDis16: 251-257.
75. Ganendren R, Carter E, Sorrell T, Widmer F, Wright L. 2006. Phospholipase B activity enhances adhesion of Crypto-coccus neoformans to a human lung epithelial cell line. Microbes Infect 8: 1006-1015.
76. Garcia-Hermoso D, Dromer F, Janbon G. 2004. Cryptococ-cus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun 72: 3359-3365.
77. Gerik KJ, Bhimireddy SR, Ryerse JS, Specht CA, Lodge JK. 2008. PKC1 is essential for protection against both oxi-dative and nitrosative stresses, cell integrity, and normal manifestation ofvirulence factors in the pathogenic fun-gus Cryptococcus neoformans. Eukaryot Cell 7: 1685-1698.
78. Gilbert NM, Donlin MJ, Gerik KJ, Specht CA, Djordjevic JT, Wilson CF, Sorrell TC, Lodge JK. 2010. KRE genes are required for i-1,6-glucan synthesis, maintenance of capsule architecture and cell wall protein anchoring in Cryp-tococcus neoformans. Mol Microbiol 76: 517-534.
79. Gilbert NM, Lodge JK, Specht CA. 2011. The cell wall of Cryptococcus.InCryptococcus, from human pathogen to model yeast (ed. Heitman J, et al.), pp. 67-79. ASM, Washington, DC.
80. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. 2009. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun 77: 3491-3500.
81. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. 2001. Serologic evidence for Cryp-tococcus neoformans infection in earlychildhood. Pediat-rics 107: e66.
82. Granger DL, Perfect JR, Durack DT. 1985. Virulence of Cryptococcus neoformans. Regulation ofcapsule synthesis by carbon dioxide. J Clin Invest 76: 508-516.
83. Griffith CL, Klutts JS, Zhang L, Levery SB, Doering TL. 2004. UDP-glucose dehydrogenase plays multiple roles in the biologyof the pathogenic fungus Cryptococcus neoformans. JBiol Chem 279: 51669-51676.
84. Gyawali R, Lin X. 2013. Prezygotic and postzygotic control of uniparental mitochondrial DNA inheritance in Cryp-tococcus neoformans. mBio 4: e00112-00113.
85. Hawksworth DL, Crous PW, Redhead SA. 2011. The Am-sterdam declaration on fungal nomenclature. IMA Fun-gus 2: 105-112.
86. Haynes BC, Skowyra ML, Spencer SJ, Gish SR, Williams M, Held EP, Brent MR, Doering TL. 2011. Toward an inte-grated model of capsule regulation in Cryptococcus neo-formans. PLoS Pathog 7: e1002411.
87. Heiss C, Klutts JS, Wang Z, Doering TL, Azadi P. 2009. The structure of Cryptococcus neoformans galactoxylo-mannan contains [beta]-D-glucuronic acid. Carbohydr Res 344: 915-920.
88. Heiss C, Skowyra ML, Liu H, Klutts JS, Wang Z, Williams M, Srikanta D, Beverley SM, Azadi P, Doering TL. 2013. Unusual galactofuranose modification of a capsule poly-saccharide in the pathogenic yeast Cryptococcus neofor-mans. JBiol Chem 288: 10994-11003.
89. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL. 2004. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): Epidemiol-ogy, microbiology and histopathology. J Med Microbiol 53: 935-940.
90. Hsueh Y-P, Metin B, Findley K, Rodriguez-Carres M, Heit-man J. 2011a. The mating type locus of Cryptococcus: Evolution of genetic clusters governing sex determination and sexual reproduction from the phylogenomic per-spective. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 139-149. ASM, Washington, DC.
91. K.J. Kwon-Chung et al. Hsueh YP, Lin X, Kwon-Chung KJ, Heitman J. 2011b. Sexual reproduction of Cryptococcus.InCryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 81-96. ASM, Washington, DC.
92. Idnurm A, Heitman J. 2005. Light controls growth and development via a conserved pathway in the fungal kingdom. PLoS Biol 3: 615-626.
93. Idnurm A, Heitman J. 2010. Ferrochelatase is a conserved downstream target of the blue light-sensing white collar complex in fungi. Microbiol 156: 2393-2407.
94. Idnurm A, Reedy JL, Nussbaum JC, Heitman J. 2004. Cryp-tococcus neoformans virulence gene discovery through insertional mutagenesis. Eukaryot Cell 3: 420-429.
95. Idnurm A, Walton FJ, Floyd A, ReedyJL, Heitman J. 2009. Identification of ENA1 as a virulence gene of the human pathogenic fungus Cryptococcus neoformans through sig-nature-tagged insertional mutagenesis. Eukaryot Cell 8: 315-326.
96. Ikeda R, Sugita T, Jacobson ES, Shinoda T. 2003. Effects of melanin upon susceptibility of Cryptococcus to antifun-gals. Microbiol Immunol 47: 271-277.
97. Jacobson ES, Hong JD. 1997. Redox buffering by melanin and Fe(II) in Cryptococcus neoformans. J Bacteriol 179: 5340-5346.
98. Jacobson ES, Ayers DJ, Harrell AC, Nicholas CC. 1982. Genetic and phenotypic characterization ofcapsule mutants ofCryptococcus neoformans. JBacteriol 150: 1292-1296.
99. Janbon G, Himmelreich U, Moyrand F, Improvisi L, Dromer F. 2001. Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol 42: 453-467.
100. Janbon G, Ormerod KL, Paulet D, Byrnes EJ, Yadav V, Chatterjee G, Mullapudi N, Hon C-C, Billmyre R.B, Brunel F, et al. 2014. Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complexRNA expression and microevolution leading to virulence attenuation. PLos Genet 10: e1004261.
101. Jung WH, Sham A, White R, Kronstad JW. 2006. Iron regulation of the major virulence factors in the AIDS-asso-ciated pathogen Cryptococcus neoformans. PLoS Biol 4: e410.
102. Jung WH, Sham A, Lian T, Singh A, Kosman DJ, Kronstad JW. 2008. Iron source preference and regulation of iron uptake in Cryptococcus neoformans. PLoS Pathog 4: e45.
103. Jung WH, Hu G, Kuo W, Kronstad JW. 2009. Role offerrox idases in iron uptake and virulence of Cryptococcus neo-formans. Eukaryot Cell 8: 1511-1520.
104. Jung WH, Saikia S, Hu G, Wang J, Fung CK, D'Souza C, White R, Kronstad JW. 2010. HapX positivelyand negatively regulates the transcriptional response to iron dep-rivation in Cryptococcus neoformans. PLoS Pathog 6: e1001209.
105. Jung KW, Strain AK, Nielsen K, Jung KH, Bahn YS. 2012. Two cation transporters Ena1 and Nha1 cooperatively modulate ion homeostasis, antifungal drug resistance, and virulence of Cryptococcus neoformans via the HOG pathway. Fungal Genet Biol 49: 332-345.
106. Kavanaugh LA, Fraser JA, Dietrich FS. 2006. Recent evolu-tion ofthe human pathogen Cryptococcus neoformans by intervarietal transferofa 14-gene fragment. Mol BiolEvol 23: 1879-1890.
107. Khan ZU, Randawa HS, Sandhu RS. 1977. Carriage ofCryp-tococcusneoformans in the crops ofpigeons. JMedMicro biol 11: 215-218.
108. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W. 2004. A rare genotype ofCryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci 101: 17258 17263.
109. Klengel T, Liang W-J, Chaloupka J, Ruoff C, Schroppel K, Naglik JR, Eckert SE, Mogensen EG, Haynes K, Tuite MF, et al. 2005. Fungal adenylyl cyclase integrates CO2 sensing with cAMP signaling and virulence. Curr Biol 15: 2021-2026.
110. Klutts JS, Doering TL. 2008. Cryptococcalxylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. J Biol Chem 283: 14327-14334.
111. Klutts JS, Levery SB, Doering TL. 2007. A i-1,2-xylosyl-transferase from Cryptococcus neoformans defines a new family of glycosyltransferases. J Biol Chem 282: 1789-17899.
112. Kmetzsch L, Staats CC, Simon E, Fonseca FL, de Oliveira DL, Sobrino L, Rodrigues J, Leal AL, Nimrichter L, Rodrigues ML, et al. 2010. The vacuolar Ca2+ exchanger Vcx1 is involved in calcineurin-dependent Ca2+ tolerance and virulence in Cryptococcus neoformans. Eukaryotic Cell 9: 1798-1805.
113. Kmetzsch L, Joffe LS, Staats CC, de Oliveira DL, Fonseca FL, Cordero RJ, Casadevall A, Nimrichter L, Schrank A, Vain-stein MH, et al. 2011. Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence. Mol Microbiol 81: 206-218.
114. Ko YJ, Yu YM, Kim GB, Lee GW, Maeng PJ, Kim S, Floyd A, Heitman J, Bahn YS. 2009. Remodeling of global tran-scription patterns of Cryptococcus neoformans genes me-diated by the stress-activated HOG signaling pathways. Eukaryot Cell 8: 1197-1217.
115. Kraus PR, Boily MJ, Giles SS, Stajich JE, Allen A, Cox GM, Dietrich FS, Perfect JR, Heitman J. 2004. Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryot Cell 3: 1249-1260.
116. Kronstad JW, Loftus BJ, Lodge JK. 2011. The Cryptococcus genomes: Tools forcomparative genomics and expression analysis. In Cryptococcus (ed. Heitman J, et al.), pp. 115126. ASM, Washington, DC.
117. Kronstad JW, Hu G, Jung WH. 2013. An encapsulation of iron homoestasis and virulence in Cryptococcus neofor mans. Trends Microbiol 21: 457-465.
118. Kumar P, Yang M, Haynes BC, Skowyra ML, Doering TL. 2011. Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol 21: 597-602.
119. Kwon-Chung KJ. 1975. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 67: 1197-1200.
120. Kwon-Chung KJ. 1976a. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 68: 821-833.
121. Kwon-Chung KJ. 1976b. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia 68: 943-946. C. neoformans and C. gattii in Cryptococcosis.
122. Kwon-Chung KJ. 1980. Nuclear genotypes of spore chains in Filobasidiella neoformans (Cryptococcus neoformans). Mycologia 72: 418-422.
123. Kwon-Chung KJ, Bennett JE. 1978. Distribution ofa and a mating types of Cryptococcus neoformans among natural and clinical isolates. Am JEpidemiol 108: 337-340.
124. Kwon-Chung KJ, Bennett JE. 1984. Epidemiologic differ-ences between the two varieties of Cryptococcus neofor-mans. Am J Epidemiol 120: 123-130.
125. Kwon-Chung KJ, Bennett JE. 1992. Medical mycology. Lea & Febiger, Philadelphia.
126. Kwon-Chung KJ, Rhodes JC. 1986. Encapsulation and mel-anin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 51: 218-223.
127. Kwon-Chung KJ, Bennett JE, Rhodes JC. 1982a. Taxonomic studies of Filobasidiella species and their anamorphs. Antonie Van Leeuwenhoek 48: 25-38.
128. Kwon-Chung KJ, Polacheck I, Bennett JE. 1982b. Improved diagnostic medium for separation of Cryptococcus neo-formans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 15: 535-537.
129. Kwon-Chung KJ, Polacheck I, Popkin TJ. 1982c. Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol 150: 1414-1421.
130. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. 2002. (1557) Proposal to conserve the name Cryptococcus gattii against C. hondrianus and C. bacillisporus (Basidiomycota, Hy-menomycetes, Tremellomycetidae). Taxon 51: 804-806.
131. Lee H, Bien CM, Hughes AL, Espenshade PJ, Kwon-Chung KJ, Chang YC. 2007. Cobalt chloride, a hypoxia-mimick-ing agent, targets sterol synthesis in the pathogenic fungus Cryptococcus neoformans. Mol Microbiol 65: 1018-1033.
132. Lee IR, Chow EW, Morrow CA, Djordjevic JT, Fraser JA. 2011. Nitrogen metabolite repression of metabolism and virulence in the human fungal pathogen Cryptococ-cus neoformans. Genetics 188: 309-323.
133. Lin X, Hull CM, Heitman J. 2005. Sexual reproduction be-tween partners of the same mating type in Cryptococcus neoformans. Nature 434: 1017-1021.
134. Lin X, Huang JC, Mitchell TG, Heitman J. 2006. Virulence attributes and hyphal growth ofCryptococcus neoformans are quantitative traits and the MATa allele enhances fil-amentation. PLoS Genet 2: e187.
135. Littman ML, Borok R. 1968. Relation ofthe pigeon to cryp-tococcosis: Natural carrier state, heat resistance and sur-vival of Cryptococcus neoformans. Mycopathol Mycol Appl 35: 329-345.
136. Litvintseva AP, Marra RE, Nielsen K, Heitman J, Vilgalys R, Mitchell TG. 2003. Evidence of sexual recombination among Cryptococcus neoformans serotype A isolates in sub-Saharan Africa. Eukaryot Cell 2: 1162-1168.
137. Litvintseva AP, Kestenbaum L, Vilgalys R, Mitchell TG. 2005. Comparative analysis ofenvironmental and clinical populations ofCryptococcus neoformans. Clin Microbiol 43: 556-564.
138. Liu L, Tewari RP, Williamson PR. 1999. Laccase protects Cryptococcus neoformans from antifungal activityofalve-olar macrophages. Infect Immun 67: 6034-6039.
139. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD, Noble SM. 2008. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135: 174-188.
140. Lodge JK, Jackson-Machelski E, Toffaletti DL, Perfect JR, Gordon JI. 1994. Targeted gene replacement demon-strates that myristoyl-CoA: protein N-myristoyltransfer-ase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci 91: 12008-12012.
141. Loftus BJ, Fung E, Roncaglia P, Rowley D, Amedeo P, Bruno D, Vamathevan J, Miranda M, Anderson IJ, Fraser JA, et al. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307: 1321-1324.
142. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, Cieslak PR, Kronstad JW, Morshed MG, Bartlett KH. 2007. Spread ofCryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 42-50.
143. Martinez LR, Casadevall A. 2006. Susceptibility of Crypto-coccus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50: 1021-1033.
144. McClelland CM, Chang YC, Varma A, Kwon-Chung KJ. 2004. Uniqueness of the mating system in Cryptococcus neoformans. Trends Microbiol 12: 208-212.
145. Meyer W, Gilgado F, Ngamskulrungroj P, Trilles LH, Hagen F, Castaneda E, Boekhout T. 2011. Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 327-357. ASM, Wash ington, DC.
146. Mitchell TG, Castaneda E, Niersen K, Wanke BMSL. 2011. Environmental niches for Cryptococcus neoformans and Cryptococcus gattii.InCryptococcus: From human patho-gen to model yeast (ed. Heitman J, et al.), pp. 237-259. ASM, Washington, DC.
147. Mody CH, Toews GB, Lipscomb MF. 1988. Cyclosporin A inhibits the growth of Cryptococcus neoformans in a mu-rine model. Infect Immun 56: 7-12.
148. Mogensen EG, Janbon G, Chaloupka J, Steegborn C, Fu MS, Moyrand F, Klengel T, Pearson DS, Geeves MA, Buck J, et al. 2006. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryot Cell 5: 103-111.
149. Morrow CA, Lee IR, Chow EW, Ormerod KL, Goldinger A, Byrnes EJ 3rd, Nielsen K, Heitman J, Schirra HJ, Fraser JA. 2012. A unique chromosomal rearrangement in the Cryptococcus neoformans var. grubii type strain enhances key phenotypes associated with virulence. mBio 3: e00310-11.
150. Moyrand F, Janbon G. 2004. UGD1, encoding the Crypto-coccus neoformans UDP-glucose dehydrogenase, is essen-tial for growth at 37°C and for capsule biosynthesis. Eu-karyotCell 3: 1601-1608.
151. Moyrand F, Klaproth B, Himmelreich U, Dromer F, Janbon G. 2002. Isolation and characterization of capsule struc-ture mutant strains of Cryptococcus neoformans. Mol Mi crobiol 45: 837-849.
152. Moyrand F, Fontaine T, Janbon G. 2007. Systematic capsule gene disruption reveals the central role of galactose me-tabolism on Cryptococcus neoformans virulence. Mol Mi-crobiol 64: 771-781.
153. Moyrand F, Lafontaine I, Fontaine T, Janbon G. 2008. UGE1 and UGE2 regulate the UDP-glucose/UDP-galactose K.J. Kwon-Chung et al. equilibrium in Cryptococcus neoformans. Eukaryot Cell 7: 2069-2077.
154. Narasipura SD, Ault JG, Behr MJ, Chaturvedi V, Chaturvedi S. 2003. Characterization ofCu,Zn superoxide dismutase (SOD1) gene knock-out mutant of Cryptococcus neofor-mans var. gattii: Role in biology and virulence. Mol Mi-crobiol 47: 1681-1694.
155. Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, Tsui KM, Mitchell TG, Vainstein MH, Meyer W. 2009a. Genetic diversity of the Cryptococcus species com-plex suggests that Cryptococcus gattii deserves to have varieties. PLoS ONE 4: e5862.
156. Ngamskulrungroj P, Himmelreich U, Breger JA, Wilson C, Chayakulkeeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, et al. 2009b. The treha-lose synthesis pathway is an integral part ofthe virulence composite for Cryptococcus gattii. Infect Immun 77: 4584-4596.
157. Ngamskulrungroj P, Price J, Sorrell T, Perfect JR, Meyer W. 2011. Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. PLoS ONE 6: e16076.
158. Ngamskulrungroj P, Chang Y, Hansen B, Bugge C, Fischer E, Kwon-Chung KJ. 2012a. Characterization of the chro-mosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS ONE 7: e33022.
159. Ngamskulrungroj P, Chang Y, Roh J, Kwon-Chung KJ. 2012b. Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii, the two etiologic agents of cryptococcosis. PLoS ONE 7: e34258.
160. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012c. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3: e00103-00112.
161. Ni M, Feretzaki M, Li W, Floyd-Averette A, Mieczkowski P, Dietrich FS, Heitman J. 2013. Unisexual and heterosexual meiotic reproduction generate aneuploidy and pheno-typic diversity de novo in the yeast Cryptococcus neofor-mans. PLoS Biol 11: e1001653.
162. Nielson JB, Ivey MH, Bulmer GS. 1978. Cryptococcus neo-formans: Pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect Immun 20: 262-266.
163. Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, Travassos LR, Casadevall A, Rodrigues ML. 2007. Self-aggregation of Cryptococcus neoformans capsular glucu-ronoxylomannan is dependent on divalent cations. Eukaryot Cell 6: 1400-1410.
164. Nosanchuk JD, Casadevall A. 2006. Impact of melanin on microbial virulence and clinical resistance to antimicro-bial compounds. Antimicrob Agents Chemother 50: 3519-3528.
165. Noverr MC, Cox GM, Perfect JR, Huffnagle GB. 2003. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun 71: 1538-1547.
166. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. 1997. Calcineurin is required for virulence of Cryptococ cus neoformans. EMBO 16: 2576-2589.
167. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB. 2004. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am Pathol 164: 1761-1771.
168. Olszewski MA, Zhang Y, Huffnagle GB. 2010. Mechanisms of cryptococcal virulence and persistence. Future Micro-biol 5: 1269-1288.
169. O'Meara TR, Alspaugh JA. 2012. The Cryptococcus neofor-mans capsule: A sword and a shield. Clin Microbiol Rev 25: 387-408.
170. O'Meara TR, Norton D, Price MS, Hay C, Clements MF, Nichols CB, Alspaugh JA. 2010. Interaction ofCryptococ-cus neoformans Rim101 and protein kinase A regulates capsule. PLoS Pathog 6: e1000776.
171. O'Meara TR, Holmer SM, Selvig K, Dietrich F, Alspaugh JA. 2013. Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. mBio 4: e00522-12.
172. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis JL, Huffnagle GB, Toews GB, Olszewski MA. 2009. Cryptococcal urease promotes the accumula-tion of immature dendritic cells and a non-protective T2 immune response within the lung. Am Pathol 174: 932-943.
173. Panepinto J, Komperda K, Frases S, Park YD, Djordjevic JT, Casadevall A, Williamson PR. 2009. Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. MolMicrobiol 71: 1165-1176.
174. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pap-pas PG, Chiller TM. 2009. Estimation ofthe current global burden ofcryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
175. Park BJ, Lockhart SR, Brandt ME, Chiller TM. 2011. Public health importance of cryptococcal disease: Epidemiolo-gy, burden, and control. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 585-593. ASM, Washington, DC.
176. Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, Sicard D. 1994. Increased fluconazole resistance ofCryptococcus neoformans isolated from a pa-tient with AIDS and recurrent meningitis. Clin Infect Dis 19: 975-976.
177. Perfect JR. 2006. Cryptococcus neoformans: The yeast that likes it hot. FEMS Yeast Res 6: 463-468.
178. Perfect JR. 2010. Cryptococcus neoformans In Principles and practice of infectious diseases (ed. Mandell GL, et al.), pp. 3287-3303. Churchill Livingstone, Philadelphia.
179. Perfect JR, Ketabchi N, Cox GM, Ingram CW, Beiser CL. 1993. Karyotyping of Cryptococcus neoformans as an ep-idemiological tool. J Clin Microbiol 31: 3305-3309.
180. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases societyofAmerica. Clin Infect Dis 50: 291-322.
181. Petter R, Kang BS, Boekhout T, Davis BJ, Kwon-Chung KJ. 2001. A survey of heterobasidiomycetous yeasts for the presence ofthe genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59. Microbiol 147: 2029-2036.
182. Pfaller MA, Lodge JK, Ghannoum MA. 2011. Drug resis-tance in Cryptococcus: Epidemiology and molecular C. neoformans and C. gattii in Cryptococcosis mechanisms. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 203-216. ASM, Washington, DC.
183. Polacheck I, Hearing VJ, Kwon-Chung KJ. 1982. Biochem-ical studies of phenoloxidase and utilization ofcatechol-amines in Cryptococcus neoformans. J Bacteriol 150: 1212-1220.
184. Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L, Morace G, Fadda G. 2003. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol 47: 357-371.
185. Pukkila-Worley R, Gerrald QD, Kraus PR, Boily MJ, Davis MJ, Giles SS, Cox GM, Heitman J, Alspaugh JA. 2005. Transcriptional networkofmultiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryot Cell 4: 190-201.
186. Reese AJ, Doering TL. 2003. Cell wall a-1,3-glucan is re-quired to anchor the Cryptococcus neoformans capsule. MolMicrobiol 50: 1401-1409.
187. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, Bose I, Kim MJ, Skau C, Yang S, et al. 2007. Loss of cell wall a(1-3) glucan affects Cryptococcus neoformans from ul-trastructure to virulence. Mol Microbiol 63: 1385-1398.
188. Rhodes JC, Polacheck I, Kwon-Chung KJ. 1982. Phenolox-idase activity and virulence in isogenic strains of Cryptococcus neoformans. Infect Immun 36: 1175-1184.
189. Rivera J, Feldmesser M, Cammer M, Casadevall A. 1998. Organ-dependent variation ofcapsule thickness in Cryp-tococcus neoformans during experimental murine infec-tion. Infect Immun 66: 5027-5030.
190. Rodero L, Mellado E, Rodriguez AC, Salve A, Guelfand L, Cahn P, Cuenca-Estrella M, Davel G, Rodriguez-Tudela JL. 2003. G484S amino acid substitution in lanosterol 14-a demethylase (ERG11) is related to fluconazole re-sistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother 47: 3653-3656.
191. Rodrigues ML, Djordjevic JT. 2012. Unravelling secretion in Cryptococcus neoformans: More than one way to skin a cat. Mycopathologia 173: 407-418.
192. Rodrigues ML, Alvarez M, Fonseca FL, Casadevall A. 2008. Binding of the wheat germ lectin to Cryptococcus neofor-mans suggests an association ofchitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell 7: 602-609.
193. Rosa e Silva LK, Staats CC, Goulart LS, Morello LG, Pele-grinelli Fungaro MH, Schrank A, Vainstein MH. 2008. Identification of novel temperature-regulated genes in the human pathogen Cryptococcus neoformans using rep-resentational difference analysis. Res Microbiol 159: 221-229.
194. Ruiz A, Nielsen JB, Bulmer GS. 1981. Control of Cryptococ-cus neoformans in nature by biotic factors. Sabouraudia 20: 21-29.
195. Saijo T, Chen J, Chen SC-A, Rosen LB, Yi J, Sorrell TC, Bennett JE, Holland SM, Brown SK, Kwon-Chung KJ. 2014. Anti-GM-CSF autoantibodies are a risk factor for central ner-vous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5: e00912-14.
196. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, William-son PR. 1996. Effect of the laccase gene CNLAC1,on virulence of Cryptococcus neoformans. J Exp Med 184: 377-386.
197. Salyer WR, Salyer DC, Baker RD. 1974. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis 130: 74-77.
198. Samson RA, Stalpers JA, Weijman AC. 1983. On the taxon-omyofthe entomogenous fungus Filobasidiella arachno-phila. Antonie Van Leeuwenhoek 49: 447-456.
199. Sanfelice F. 1894. Contributo alla morphologia e biologiadei blastomiceti che si sviluppano nei succhi di alcuni frutti [Contribution on the morphology and biologyofblasto-myces that grows in certain fruit juice]. Ann Igien 4: 463-495.
200. Sarosi GA, Parker JD, Doto IL, Tosh FE. 1969. Amphotericin B in cryptococcal meningitis. Long-term results oftreat-ment. Ann Intern Med 71: 1079-1087.
201. Schneider RdO, Fogaca NdS S, Kmetzsch L, Schrank A, Vainstein MH, Staats CC. 2012. Zap1 regulates zinc ho-meostasis and modulates virulence in Cryptococcus gattii. PLoS ONE 7: e43773.
202. Seeliger HPR. 1956. Use ofa urease test for the screening and identification of cryptococci. JBacteriol 72: 127-131.
203. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, Kubes P, Mody CH. 2010. Real-time imaging oftrapping and ure-ase-dependent transmigration of Cryptococcus neofor-mans in mouse brain. J Clin Invest 120: 1683-1693.
204. Singh A, Panting RJ, Varma A, Saijo T, Waldron KJ, Jong A, Ngamskulrungroj P, Chang YC, Rutherford JC, Kwon-Chung KJ. 2013. Factors required for activation ofurease as a virulence determinant in Cryptococcus neoformans. mBio 4: e00220-13.
205. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. 2009. Heteroresistance to fluconazole in Cryptococcus neofor-mans is intrinsic and associated with virulence. Antimi-crob Agents Chemother 53: 2804-2815.
206. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. 2010. Cryp-tococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog 6: e1000848.
207. Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ. 2012. Identification of a Crypto-coccus neoformans cytochrome P450 lanosterol 14a-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemo ther 56: 1162-1169.
208. Sionov E, Chang YC, Kwon-Chung KJ. 2013. Azole hetero-resistance in Cryptococcus neoformans: Emergence of re-sistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob Agents Chemother 57: 5127-5130.
209. Sorrell TC, Chen SCA, Phillips P, Marr KA. 2011. Clinical perspectives on Cryptococcus neoformans and Cryptococ-cus gattii: Implications for diagnosis and management. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 595-606. ASM, Washington, DC.
210. Staib F. 1962a. Cryptococcus neoformans beim Kanarienvo-gel. Z Bacteriol 185: 129-134.
211. Staib F. 1962b. Cryptococcus neoformans und Guizotia abys-sinica (Syn G. oleifera) Farbreaktion fur Cr. neoformans [Cryptococcus neoformans and Guizotia abyssinica (Syn K.J. Kwon-Chung et al. G. oleifera) color reaction for Cr. neoformans]. ZHyg 148: 466-475.
212. Staib F, Mishra SK, Able T, Blisse A. 1976. Growth ofCryp-tococcus neoformans on uric acid agar. Z Bakteriol 236: 374-385.
213. Stanton BC, Giles SS, Staudt MW, Kruzel EK, Hull CM. 2010. Allelic exchange ofpheromones and their receptors reprograms sexual identity in Cryptococcus neoformans. PLoS Genet 6: e1000860.
214. Steen BR, Lian T, Zuyderduyn S, MacDonald WK, Marra M, Jones SJ, Kronstad JW. 2002. Temperature-regulatedtran-scription in the pathogenic fungus Cryptococcus neofor-mans. Genome Res 12: 1386-1400.
215. Steenbergen JN, Shuman HA, Casadevall A. 2001. Crypto-coccus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci 98: 15245-15250.
216. Steinbach WJ, Reedy JL, Cramer RA Jr., Perfect JR, Heitman J. 2007. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Micro-biol 5: 418-430.
217. Stephen C, Lester S, Black W. 2002. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can J Vet Res 43: 792-794.
218. Stoddard JL, Cutler EC. 1916. Torula infection in man, Vol. 6, pp. 1-98. Rockefeller Institute for Medical Research, New York.
219. Sun S, Xu J. 2009. Chromosomal rearrangements between serotype A and D strains in Cryptococcus neoformans. PLoS ONE 4: e5524.
220. Swinne-Desgain D. 1975. Cryptococcus neoformans of sap-rophytic origin. Sabouraudia 13: 303-308.
221. Tangen KL, Jung WH, Sham AP, Lian T, Kronstad JW. 2007. The iron and cAMP-regulated gene SIT1 influences fer-rioxamine B utilization, melanization and cell wall struc-ture in Cryptococcus neoformans. Microbiol 153: 29-41.
222. Toffaletti DL, Rude TH, Johnston SA, Durack DT, Perfect JR. 1993. Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. JBacteriol 175: 1405-1411.
223. Torres-Guererro H, Edman JC. 1994. Melanin-deficient mu-tants of Cryptococcus neoformans. J Med Vet Mycol 32: 303-313.
224. Vaishnav VV, Bacon BE, O'Neill M, Cherniak R. 1998. Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydr Res 306: 315-330.
225. van Duin D, Casadevall A, Nosanchuk JD. 2002. Melaniza-tion of Cryptococcus neoformans and Histoplasma cap-sulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 46: 3394-3400.
226. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. 2004. Effects of voriconazole on Cryptococcus neofor-mans. Antimicrob Agents Chemother 48: 2014-2020.
227. Varma A, Kwon-Chung KJ. 2010. Heteroresistance of Cryp-tococcus gattii to fluconazole. Antimicrob Agents Chemo ther 54: 2303-2311.
228. Vartivarian SE, Anaissie EJ, Cowart RE, Sprigg HA, Tingler MJ, Jacobson ES. 1993. Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis 167: 186-190.
229. Verse M. 1914. Uber einen Fall von generalisierter Blasto-mykose beim menschen [About a case of generalized human blastomycosis]. Verh Dtsch Pathol Ges 17: 275-278.
230. Vuillemin P. 1901. Les blastomycetes pathogens. Rev Gen Sci Pures Appl 12: 732-751.
231. Walton FJ, Idnurm A, Heitman J. 2005. Novel gene func-tions required for melanization of the human pathogen Cryptococcus neoformans. MolMicrobiol 57: 1381-1396.
232. Wang Y, Casadevall A. 1994. Susceptibilityofmelanized and nonmelanized Cryptococcus neoformans to nitrogen and oxygen-derived oxidants. Infect Immun 62: 3004-3007.
233. Wang Y, Aisen P, Casadevall A. 1995. Cryptococcus neofor-mans melanin and virulence: Mechanism ofaction. Infect Immun 63: 3131-3136.
234. Wang ZA, Griffith CL, Skowyra ML, Salina N, Williams M, Maier EJ, Gish SR, Liu H, Brent MR, Doering TL. 2014. The dual GDP-mannose transporters of Cryptococcus neoformans and their role in biology and virulence. Eu karyot Cell 13: 832-842.
235. Warpeha KM, Park YD, Williamson PR. 2013. Susceptibility of intact germinating Arabidopsis thaliana to human fun-gal pathogens Cryptococcus neoformans and C. gattii. Appl Environ Microbiol 79: 2979-2988.
236. Waterman SR, Hacham M, Hu G, Zhu X, Park Y-D, Shin S, Panepinto J, Valyi-Nagy T, Beam C, Husain S, et al. 2007a. Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans. J Clin Invest 117: 794-802.
237. Waterman SR, Hacham M, Panepinto J, Hu G, Shin S, Wil-liamson PR. 2007b. Cell wall targeting oflaccase ofCryp-tococcus neoformans during infection of mice. Infect Immun 75: 714-722.
238. Waterman SR, Park Y-D, Raja M, Qiu J, Hammoud DA, O'Halloran TV, Williamson PR. 2012. Role of CTR4 in the virulence of Cryptococcus neoformans. mBio 3: e00285-12.
239. Whitney LC, Bicanic T. 2014. Treatment principles for Candida and Cryptococcus. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a024158.
240. Wills EA, Roberts IS, Del Poeta M, Rivera J, Casadevall A, Cox GM, Perfect JR. 2001. Identification and charac-terization of the Cryptococcus neoformans phosphoman-nose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol 40: 610-620.
241. Wilson DE, Bennett JE, Bailey JW. 1968. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 127: 820-823.
242. Wozniak KL, Olszewski M, Wormley FL. 2012. Hostimmune responses against pulmonary fungal pathogens, pp. 85-127. InTech, Rijeka, Croatia.
243. Wright LC, Santangelo RM, Ganendren R, Payne J, Djord-jevic JT, Sorrell TC. 2007. Cryptococcal lipid metabolism: Phospholipase B1 is implicated in transcellular meta-bolism of macrophage-derived lipids. Eukaryot Cell 6: 37-47.
244. Xu J, Ali RY, Gregory DA, Amick D, Lambert SE, Yoell HJ, Vilgalys RJ, Mitchell TG. 2000. Uniparental mitochon-drial transmission in sexual crosses in Cryptococcus neo-formans. Curr Microbiol 40: 269-273.C. neoformans and C. gattii in Cryptococcosis CU.
245. Xu J-P, Manosuthi W, Banerjee U. 2011. Cryptococcosis in Asia. In Cryptococcus: From human pathogen to model yeast (ed. Heitman J, et al.), pp. 287-297. ASM, Washington, DC.
246. Xue C, Tada Y, Dong X, Heitman J. 2007. The human fungal pathogen Cryptococcus can complete its sexual cycle during a pathogenic association with plants. Cell Host Microbe 1: 263-273.
247. Yan Z, Hull CM, Heitman J, Sun S, Xu J. 2004. SXI1acon-trols uniparental mitochondrial inheritance in Crypto-coccus neoformans. Curr Biol 14: R743-R744.
248. Yang J, Li D, Liu X, Pan J, Yan B, Zhu X. 2010. Regulation of virulence factors, carbon utilization and virulence by SNF1 in Cryptococcus neoformans JEC21 and divergent actions ofSNF1 between cryptococcal strains. Fungal Ge-net Biol 47: 994-1000.
249. Yoneda A, Doering TL. 2006. A eukaryotic capsular poly-saccharide is synthesized intracellularly and secreted via exocytosis. Mol Biol Cell 17: 5131-5140.
250. Zhu X, Williamson PR. 2004. Role oflaccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res 5: 1-10.
251. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR. 2001. Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun 69: 5589-5596.
252. Zhu P, Zhai B, Lin X, Idnurm A. 2013. Congenic strains for genetic analysis of virulence traits in Cryptococcus gattii. Infect Immun 81: 2616-2625.